atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study...

PT430 – Psychedelics for Eating Disorders, Davos’ House of Psychedelics, and...

Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For...

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its...

FILAMENT HEALTH ANNOUNCES FDA APPROVAL OF TWO CLINICAL TRIALS STUDYING ITS...

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke...

Psychedelic Neuroscience Demystified: How Psychedelics Alter Consciousness and Produce Therapeutic Effects

MIND CURE ANNOUNCES CLOSING OF LNG ENERGY’S SUBSCRIPTION RECEIPT FINANCING

Navigating Psychedelics: Jewish-Informed Perspectives on Psychedelics

PT429 – From Mycophobia to Fungi Fever: The Psychedelic Space’s Growing...

Load more